| __timestamp | BioMarin Pharmaceutical Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 7890000 |
| Thursday, January 1, 2015 | 402271000 | 14456000 |
| Friday, January 1, 2016 | 476593000 | 19218000 |
| Sunday, January 1, 2017 | 554336000 | 27986000 |
| Monday, January 1, 2018 | 604353000 | 47928000 |
| Tuesday, January 1, 2019 | 680924000 | 96388000 |
| Wednesday, January 1, 2020 | 737669000 | 157743000 |
| Friday, January 1, 2021 | 759375000 | 195293000 |
| Saturday, January 1, 2022 | 854009000 | 237374000 |
| Sunday, January 1, 2023 | 937300000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and Blueprint Medicines Corporation from 2014 to 2023. Over this period, BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive expansion and investment in new therapies. In contrast, Blueprint Medicines, while starting with significantly lower expenses, has seen a staggering increase of nearly 3,600%, indicating rapid growth and scaling efforts.
BioMarin's expenses consistently outpace Blueprint's, highlighting its established market presence. However, Blueprint's exponential growth in SG&A expenses suggests a company in transition, aiming to solidify its position in the biotech landscape. This financial narrative underscores the dynamic strategies of these two companies as they navigate the challenges and opportunities in the pharmaceutical industry.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.